Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes

Diabetes Care

Volumn 37, Issue 10, 2014, Pages 2763-2773

  Diamant, Michaela ^a   Nauck, Michael A ^b   Shaginian, Rimma ^c   Malone, James K ^c   Cleall, Simon ^c   Reaney, Matthew ^c   De Vries, Danielle ^c   Hoogwerf, Byron J ^c   MacConell, Leigh ^d   Wolffenbuttel, Bruce H R ^e  

^a Diabetes Center   (Netherlands)

^b Diabetes Center   (Germany)

^c ELI LILLY AND COMPANY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; ANTIDIABETIC AGENT; GLARGINE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LONG ACTING INSULIN; PEPTIDE; VENOM;

ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONNOCTURNAL HYPOGLYCEMIA; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VOMITING; AGED; AGONISTS; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; HYPERGLYCEMIA; MEAL; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MEALS; METFORMIN; MIDDLE AGED; PEPTIDES; QUALITY OF LIFE; RECEPTORS, GLUCAGON; TREATMENT OUTCOME; VENOMS;

EID: 84908164432     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0876     Document Type: Article

References (35)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
2. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005- 2012.
3. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154: 103-112.
4. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013;15: 485-502.
5. Nathan DM. Time for clinically relevant comparative effectiveness studies in type 2 diabetes. Ann Intern Med 2011;154:131-132.
6. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-1369.
7. Rosenstock J, Ahmann AJ, Colon G, Scism- Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-25.
8. Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL. Randomized, openlabel, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral anti hyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010;32:896-908.
9. Kolotkin RL, Crosby RD. Psychometric evaluation of the Impact of Weight on Quality of Life- Lite questionnaire (IWQOL-Lite) in a community sample. Qual Life Res 2002;11:157-171.
10. Bradley C. The Diabetes Treatment Satisfaction Questionnaire. In Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Bradley C, Ed. Chur, Switzerland, Harwood Academic Publishers, 1994, p. 111-132.
11. Bradley C. Diabetes Treatment Satisfaction Questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999;22:530-532.
12. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with longterm treatment. Diabetes Obes Metab 2012; 14:546-554.
13. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14:910-917.
14. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treatto- Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080- 3086.
15. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36: 2489-2496.
16. Gerich J. Abnormal glucagon secretion in type 2 (noninsulin-dependent) diabetes mellitus: causes and consequences. In Diabetes Mellitus: Pathophysiology and Therapy. Creutzfeldt W, Lefebvre P, Eds. Berlin, Heidelberg, SpringerVerlag, 1989, p. 127-133.
17. Roden M, Perseghin G, Petersen KF, et al. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. J Clin Invest 1996;97:642-648.
18. Paquot N, Roulin D, Schneiter P, et al. Effects of regular insulin or insulin LISPRO on glucose metabolism after an oral glucose load in patients with type 2 diabetes mellitus. Diabetes Metab 1998;24:523-528.
19. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
20. Drucker DJ, Buse JB, Taylor K, et al.; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, noninferiority study. Lancet 2008;372:1240-1250.
21. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28: 1092-1100.
22. Pratley RE, Nauck M, Bailey T, et al.; 1860- LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallelgroup, open-label trial. Lancet 2010;375:1447- 1456.
23. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 1997;105:187- 195.
24. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008;151:123-129.
25. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012;14:675-688.
26. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
27. Holman RR, Farmer AJ, Davies MJ, et al.; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-1747.
28. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.
29. Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:882-892.
30. LindM, Jendle J, Torffvit O, Lager I. Glucagonlike peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012;6:41-46.
31. LaSalle JR Jr, Berria R. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc 2013;113:152-162.
32. Abrahamson MJ, Peters A. Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy. Ann Med 2012;44:836-846.
33. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer 2011; 11:20.
34. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013;36(Suppl. 2):S245-S252.
35. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugsdFDA and EMA assessment. N Engl J Med 2014;370:794- 797.